Intercell, Novartis vaccine goes into PhII; Pfizer's Prevnar effective in adolescents;

> Intercell has started a pivotal Phase II/III efficacy study of its Pseudomonas aeruginosa vaccine candidate. The move comes after a Phase II trial showed the vaccine reduced death rates; the vaccine is part of a strategic alliance with Novartis ($NVS). Intercell release

> PX'Therapeutics is launching a Phase I clinical trial of an HIV prophylactic vaccine as part of the EU collaborative project EuroNeut-41. PX'Therapeutics release

> Patient recruitment has started for an early clinical trial for PD01, an experimental Parkinson's disease vaccine from AFFiRiS. Article

> Pfizer's ($PFE) Prevnar, currently approved for use in infants and young children, has shown efficacy in children and young people up to the age of 17. Pfizer release

> Taiwan's Adimmune is planning clinical trials for its domestic H5N1 vaccine. Article

> Flu vaccines are safe for most children with egg allergies. News

> India welcomes the Gennova Vaccine Formulation Center, a $7.9 million facility dedicated to manufacturing vaccines. Story

> Ghana has approval from the WHO to launch four meningitis vaccines. Item

And Finally… The Infectious Disease Research Institute has received a $1 million grant to develop a leprosy diagnostic and vaccine as part of an effort to eliminate the disease. IDRI release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.